US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, January 30, 2025; Inify Laboratories AB (publ.) has been notified that the following transactions have been completed by a primary insider in Inify; Olof Sandén, board member and primary insider in Inify, has acquired 16,840 shares in Inify at an average price of SEK 4.36 per share during January 27th – 29th. After the transactions, Sandén controls 116,840 shares.     This information is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act.   For

Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, January 24, 2024; Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 23 January 2024, regarding the final results of the subsequent repair offering of shares in the Company (the "Subsequent Offering"). Inify Laboratories AB (publ.) announces that the below primary insiders were allocated new shares at the offer price in the Subsequent Offering as further specified in the attached PDMR notification forms:   -          Monsun AS, a company closely associated with board member Magne Jordanger, has been allocated 2,

Inify Laboratories – Final results of the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 9 January 2025 regarding the commencement of the

Inify Laboratories – Last day of the subscription period in the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 9 January 2025 regarding the commencement of the

Inify Laboratories – Commencement of subscription period for Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 7 January 2025 regarding the registration of a

Inify Laboratories enter into agreement with Swedish region

Inify Laboratories, a unique laboratory service that performs cancer diagnostics within pathology, has entered into an agreement with the region of Västmanland in Sweden on a pilot project with the goal of shortening waiting times for results to patients with suspected prostate cancer. Pathology in large parts of the Western world is under enormous pressure, with an extensive mission and limited resources. One of the areas affected with long and varying lead times is prostate cancer diagnostics. Most regions in Sweden have challenges in reaching the goals that have been developed within

Inify Laboratories – Registration of prospectus and upcoming launch of Subsequent Offering

STOCKHOLM – 7 January 2025 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 16 December 2024 regarding the successful private placement of 30,202,366 new shares in the Company (the "Private Placement"), and the contemplated subsequent repair offering of 3,464,300 new shares in the Company (the "Subsequent Offering"). The Company has prepared a Norwegian national prospectus for the Subsequent Offering (the "Prospectus"), which was registered with the Norwegian Register of Business Enterprises today, 7 January 2025, in accordance with

Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, December 16, 2024; Inify Laboratories AB (publ.) announces that the below primary insider was allocated new shares at the Offer Price in the Private Placement as further specified in the attached notification forms:   -          Gallivant S.à r.l. and Monsun AS, companies closely associated with board member Magne Jordanger, have been allocated 20,229,274 and 5,022,570 Private Placement Shares, respectively (in aggregate: 25,251,844 Private Placement Shares). Gallivant S.à r.l. and Monsun AS will, subject to completion of the Private Placement own 47,410,660 and

Inify Laboratories: Key information regarding potential Subsequent Offering

Reference is made to the stock exchange announcement published today, 16 December 2024, regarding the successful private placement of 30,202,366 new shares (the “Private Placement”) in Inify Laboratories AB (publ) (“Inify” or the “Company”), where it was announced that the Company will, subject to the publication of a national (Norwegian) prospectus, carry out a subsequent offering of 3,464,300 new shares in the Company with gross proceeds of the NOK equivalent of approximately SEK 15 million (the “Subsequent Offering”). The Subsequent Offering will be directed pro-rata towards all

Inify Laboratories announces successful placement of fully guaranteed private placement

STOCKHOLM – 16 December 2024 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 9 December 2024 regarding the board of directors' decision to launch a fully guaranteed private placement of 30,000,000 new shares (the “Private Placement Shares”) with gross proceeds of the NOK equivalent of approximately SEK 135 million with a minimum subscription per subscriber of the NOK equivalent of EUR 100,000 (the “Private Placement”), directed pro-rata towards existing shareholders holding more than 400,000 shares in the Company (other than Avanza

Inify Laboratories announces application periods for fully guaranteed private placement and fully guaranteed subsequent repair issue

STOCKHOLM – 9 December 2024 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the “Company”) on 15 November 2024, regarding a proposed fully guaranteed share issue generating gross proceeds of approximately SEK 150 million, and the extraordinary general meeting held 6 December 2024 which resolved to authorize the board of directors of the Company to resolve on the issuance of new shares. The board of directors has today resolved to launch the fully guaranteed private placement of 30,000,000 new shares (the “Private Placement Shares”) with gross

Inify Laboratories AB (publ) - Bulletin from the extraordinary general meeting

Today, December 6, 2024, INIFY Laboratories AB, org. no. 559345-4431 (the "Company") held an extraordinary general meeting. A total of 28,168,336 shares were represented at the general meeting, which corresponds to 62.3 percent of the total number of shares and votes in the Company. Below is a summary of the resolution that were made. The extraordinary general meeting resolved, with the requisite majority, in accordance with the Board of Directors' previously published proposal. Issue authorization The general meeting resolved, in accordance with the Board of Directors' proposal, to

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of SEK 150 million

STOCKHOLM – November 15, 2024 – reference is made to the stock exchange announcement made by Inify Laboratories AB (“Inify” or the “Company”) on 23 October 2024 regarding expansion to the UK and a potential share issue of approximately SEK 150 million. The Company will in a separate press release call for an Extraordinary General Meeting (the “EGM”) to be held on 6 December 2024 at 10:00 CET to resolve to authorize the board of directors to resolve on the issuance of new shares. Provided that the EGM resolves to authorize the board of directors to resolve on the issuance of new shares,

Inify Laboratories - notice of Extraordinary General Meeting on December 6, 2024

Stockholm – November 15, 2024 - Inify Laboratories AB (publ), a unique laboratory service provider within pathology and cancer diagnostics, hereby invites its shareholders to Extraordinary General Meeting on December 6, 2024. Please find attached the invitation including attachment, agenda and details on how to register and vote. The invitation is also available on the company's website: www.inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com.   ###   The future of pathology Inify

Inify Laboratories enter a research partnership with the Department of Molecular Medicine and Surgery at Karolinska Institutet aiming to advance precision diagnostics within prostate cancer

STOCKHOLM – November 05, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, is proud to announce a partnership with the ProMort research team at Karolinska Institutet, aimed at transforming prostate cancer diagnostics. The primary objective of this collaboration is to improve the precision of prostate cancer diagnosis through AI-driven image analysis.“When our ProMort team started the discussions with Inify, we quickly realized the power of their organization and technology. A collaboration has great potential to further advance the

Panel talk about Inify’s third quarter 2024

Inify Laboratories have decided to establish its operation to the United Kingdom and expand diagnostics to the gastrointestinal field. One of the major challenges in the UK is long and unpredictable response times and varying quality in prostate cancer care. The market is six times larger than Sweden´s in terms of patient volume, with approximately 120,000 patients annually who require diagnosis. "The national health care system NHS in the UK has a high focus on pathways for patients that are going through cancer investigations, and here is exactly where we provide unique

Inify Laboratories: Establishment in the United Kingdom and expansion into gastrointestinal diagnostics

STOCKHOLM - October 23, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, has after extensive market mapping decided to establish operations in the United Kingdom (UK).   “After our successful launch in Sweden, where we now have around 80% of the Stockholm market share, the time is right to expand. The UK market is estimated to be six times larger than Sweden’s in terms of patient volume, with approximately 120,000 patients annually who require diagnosis,” says CEO Fredrik Palm in Inify Laboratories.   The company has

Inify Laboratories gets honorable mention by the Royal Swedish Academy of Engineering Sciences (IVA) at the Smart Industry business competition 2024

STOCKHOLM - October 10, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology received an honorable mention by the Royal Swedish Academy of Engineering Sciences (IVA) during the Smart Industry business competition 2024 during the award ceremony on October 9 in Gothenburg.“Inify receives an honorable mention in the Smart Industry business competition 2024 for their ultramodern laboratory that combines an industrial approach with innovations within healthcare processes. Their technology is based on niche digital applications with unique

Panel talk about Inify’s second quarter 2024

"We are saving weeks in waiting time for patients to get the diagnosis". This and more value that Inify Laboratories can provide to its customers from day one is highlighted in this panel talk about the second quarter of 2024 with CEO Fredrik Palm, Laboratory Director Emelie Edvigsson and Ole Eikeland.Inify Laboratories continued to deliver strong growth with sales of SEK 3.6 million in the quarter – up 62% compared to Q1. By the end of June, the laboratory had been open for over a year and had diagnosed more than 1,000 patients. More details about the laboratory operations and its

INIFY Laboratories: 62% revenue growth and strong international interest

STOCKHOLM - August 21, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, continues to deliver strong growth, with sales of SEK 3.6 million in the quarter – up 62% compared to the previous quarter. Total sales for the first half of the year amounted to SEK 5.8 million, with a cash balance at the end of the second quarter of SEK 46,1 million. “We have diagnosed more than 1,000 patients since the opening of our first laboratory and our market share in Sweden has grown to around 5%, which means that the continued growth potential in

Inify Laboratories AB (publ) – summary of Annual General Meeting

Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders’ Annual General Meeting at the company's premises on May 14, 2024. A total of 30,133,104 shares were represented at the Annual General Meeting, corresponding to 66.61% of the total number of shares and votes. The AGM resolved, with the required majority, on all matters in accordance with the Board of Directors's published proposal. Below is a summary of the main decisions made, for further details please refer to the notice available on the company's website.   Adoption of the accounts The Annual General

Inify Laboratories - More diagnoses delivered in the first quarter than in the whole of 2023

STOCKHOLM - April 24, 2024 - Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, saw a 184% increase in sales in Q1 2024, compared to the previous quarter. “What we see now is the result of many years of preparation. More diagnoses were delivered in the first quarter alone than in the whole of 2023. The company’s whole organization is ready for the significant increase in sales that we foresee both this year, and the years to come,” says CEO Fredrik Palm at Inify Laboratories. Inify is experiencing a great deal of interest from new

Inify Laboratories - Annual Report 2023

Stockholm – April 11, 2024 – Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, presents its Annual Report for the fiscal year ended December 31, 2023. The annual report is attached to this press release and is also available on the company’s website: www.inify.com. Printed copies of the report will be distributed upon request sent to e-mail: ir@inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com   ###     About Inify Laboratories Inify

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media